As expected, the GVHD+ patient group had significantly higher levels of HGF, elafin, ST2 and TNFR1 than the GVHD – group and the healthy donor group (Figure 5 a–d), demonstrating the effectiveness of our system at measuring multiple biomarkers from patient samples. The gene discussed is PI3; the disease is graft versus host disease.